Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 19/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6557297 | 0.86 | GPR84 (0.51) | GPR84CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6557257 | 0.85 | GPR84 (0.50) | GPR84CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6557416 | 0.85 | GPR84 (0.50) | GPR84CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6556996 | 0.85 | GPR84 (0.50) | GPR84CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6557610 | 0.83 | GPR84 (0.77) | GPR84KDM4EMEN1KMT2A | |
| SCHEMBL6557278 | 0.82 | GPR84 (1.00) | GPR84KDM4EMEN1KMT2A | |
| SCHEMBL6557260 | 0.80 | GPR84 (0.62) | GPR84KDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL28606923 | 0.74 | GPR84 (0.47) | GPR84KDM4EMEN1KMT2A | |
| SCHEMBL297640 | 0.74 | GPR84 (0.62) | GPR84KDM4EMEN1KMT2A | |
| SCHEMBL6558522 | 0.73 | GPR84 (0.58) | GPR84KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350040-B2 | Process for preparing (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2- methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-08 | — | — | US | disclosed |
| EP-1888604-B1 | PROCESS FOR PREPARING (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110319623-A1 | PROCESS FOR PREPARING (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL | CILAG AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8039628-B2 | Isolation from mixture of stereoisomers; optical resolution of enantiomorphs | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-18 | — | — | US | disclosed |
| US-20080200683-A1 | Process for Preparing (Alpha S, Beta R)-6-Bromo-Alpha-[2-(Dimethylamino) Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | US | disclosed |
| EP-1038877-B1 | Binaphthol monophosphoric acid derivative and its use | TOSOH CORP (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6274745-B1 | CATALYST | TOSOH CORPORATION (JP) | 2001-08-14 | — | — | US | disclosed |
| EP-1038877-A1 | Binaphthol monophosphoric acid derivative and its use | Tosoh Corporation (JP) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200683-A1 | Process for Preparing (Alpha S, Beta R)-6-Bromo-Alpha-[2-(Dimethylamino) Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol | LBR, ADRA1A, ADRA1D | GPR84 1474/4885KDM4E 1189/4885MEN1 1168/4885 |
| US-20110319623-A1 | PROCESS FOR PREPARING (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL | LBR, ADRA1A, ADRA1D | GPR84 1474/4885KDM4E 1189/4885MEN1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.